ArticleTranslational lung cancer research2025
Serum levels of C-terminal peptides of alpha-1 antitrypsin as potential biomarkers in non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Circulating alpha-1 antitrypsin and its c-terminal peptides differentiate bacterial from viral community-acquired pneumonia.Journal of translational medicine · 2026Article
- Clinical peptidomics for respiratory diseases: matrices, workflows, and translation towards treatable traits, with a focus on COPD.Clinical proteomics · 2026Review
- Protein Fragments: From Biomarkers to Therapeutic Targets-A Focus on α1-Antitrypsin-Derived Peptides.Mediators of inflammation · 2026Review
- Circulating C-terminal peptides and polymers of alpha-1 antitrypsin as putative markers of pediatric Pi*ZZ liver disease.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Alpha-1 antitrypsin (AAT) has been identified as a prognostic factor for lung cancer survival. Proteolytic cleavage of AAT by specific enzymes generates C-terminal peptides with varying lengths and biological activities. So far, the role of these peptides in NSCLC progression and prognosis remains unexplored. In this study, we aim to investigate the prognostic potential of AAT peptides in patients with NSCLC. Methods: Serum levels of the 9 peptides (C22, C36, C37, C39, C40, C42, C43, C44 and C45) were simultaneously quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Correlations between peptide levels and full-length AAT protein, clinical parameters, and patient outcomes were analyzed. Additionally, the potential of these peptides as prognostic markers was evaluated, and changes in the AAT-to-peptide ratio were assessed in relation to tumor progression. Results: Peptides C36, C37, and C42 showed the highest levels and strong correlations with each other, AAT, a precursor of these peptides, and a trend-level association with C-reactive protein (CRP) levels. Notably, peptide levels were significantly associated with smoking status. In a multivariate Cox hazard model, C42 emerged as an independent prognostic factor for overall survival when combined with clinical parameters. Following surgical tumor resection, the concentrations of these peptides increased, along with their ratio to AAT, suggesting a tumor-related impact on AAT levels and its peptide generation. Conclusions: Our study highlights the potential prognostic value of AAT-derived peptides in NSCLC. Among the analyzed peptides, C36, C37, and C42 showed the strongest correlations with full-length AAT, and their levels were affected by smoking status. Notably, C42 emerged as an independent prognostic marker for overall survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.